Adult female mosquitoes require a vertebrate blood meal to develop eggs and continue their life 10 cycle. During blood feeding, mosquito saliva is injected at the bite site to facilitate blood meal 11 acquisition through anti-hemostatic compounds that counteract blood clotting, platelet 12 aggregation, vasoconstriction and host immune responses. D7 proteins are among the most 13 abundant components of the salivary glands of several blood feeding insects. They are members 14 of a family of proteins that have evolved through gene duplication events to encode D7 proteins 15 of several lengths. Here, we examine the ligand binding specificity and physiological relevance 16 of two D7 long proteins, CxD7L1 and CxD7L2, from Culex quinquefasciatus mosquitoes, the 17 vector of medical and veterinary diseases such as filariasis, avian malaria, and West Nile virus 18 infections. CxD7L1 and CxD7L2 were assayed by microcalorimetry for binding of potential host 19 ligands involved in hemostasis, including bioactive lipids, biogenic amines, and 20 nucleotides/nucleosides. CxD7L2 binds serotonin, histamine, and epinephrine with high affinity 21 as well as the thromboxane A2 analog U-46619 and several cysteinyl leukotrienes, as previously 22 described for other D7 proteins. CxD7L1 does not bind any of the ligands that are bound by 23 CxD7L2. Unexpectedly, CxD7L1 exhibited high affinity for adenine nucleotides and 24 nucleosides, a binding capacity not reported in any D7 family member. We solved the crystal 25 structure of CxD7L1 in complex with bound ADP to 1.97 Å resolution. The binding pocket for 26 ADP is located between the two domains of CxD7L1, whereas all known D7s bind ligands either 27 within the N-terminal or the C-terminal domains. We demonstrated that these two CxD7 long 28 proteins inhibit human platelet aggregation in ex vivo experiments. CxD7L1 and CxD7L2 help 29 blood feeding in mosquitoes by scavenging host molecules that promote vasoconstriction, 30 platelet aggregation, itch, and pain at the bite site. The novel ADP-binding function acquired by CxD7L1 evolved to enhance blood feeding in mammals where ADP plays a key role in platelet 32 aggregation. 33 Culex quinquefasciatus (Diptera: Culicidae) commonly known as the southern house mosquito, 35 is a vector of medical and veterinary importance of filaria parasites, including Wuchereria 36 bancrofti and Dirofilaria immitis 1, 2 and avian malaria parasites (Plasmodium relictum) 3 . They 37 also can transmit several arboviruses including Rift Valley fever, West Nile, St. Louis or 38 Western equine encephalitis viruses 4, 5 . Adult female mosquitoes need to acquire vertebrate 39 blood for egg development. During blood feeding, mosquito saliva is injected at the bite site and 40 facilitates blood meal acquisition through anti-hemostatic compounds that prevent blood clotting, 41 platelet aggregation and vasoconstriction as well as host immune responses 6 .
Introduction
anti-CxD7L1 IgG was pre-adsorbed with CxD7L2 and anti-CxD7L2 IgG was pre-adsorbed with 165 adenine (e). In panels j-f other purine and pyrimidine nucleotides and related substances showed no binding to adenosine monophosphate (i) and polyphosphate (j). The insets show the names and chemical formulas for these compounds.
169
Our biochemical characterization shows that CxD7L1 specifically binds the purine nitrogenous 170 base adenine, its nucleoside (adenosine), and nucleotide derivates: AMP, ADP, and ATP, with 171 the highest affinity to ATP and ADP ( Fig. 3a-e ). The binding is adenine-specific, as no binding 172 was observed with other purine or pyrimidine nucleotides such as GTP or TTP ( Fig. 3f -g).
173
Although adenine is essential for binding, CxD7L1 did not bind to adenosine 3′-monophosphate 174 (3'-AMP) or cyclic AMP ( Fig. 3h- . 3j ). Furthermore, CxD7L1 did not bind to inosine ( Supplementary Fig. 2 
198
To gain insights into the mechanism of CxD7L2 binding to biogenic amines and eicosanoids, the for CxD7L2-serotonin see Table 1 ). We concluded that CxD7L2-CT is responsible for the 924.6 cal/mol; for CxD7L2-LTD4 see Table 1 ). These results demonstrate that lipids and 211 biogenic amines bind to the CxD7L2 protein independently through different binding pockets, 212 with lipids binding to the N-terminal pocket and biogenic amines to the C-terminal pocket, 213 similar to the binding mechanism of AeD7 protein from Ae. aegypti 11 . 214
Crystal structure of Culex quinquefasciatus CxD7L1

215
To further characterize the mechanism of the novel adenine nucleoside/nucleotide D7 binding, 216 we solved the crystal structure of CxD7L1 in complex with ADP. The structure of CxD7L1 was 217 determined by molecular replacement using Phaser by employing separate, manually constructed 218 search models for the N-terminal and C-domains based on the crystal structure of Anopheles stephensi AnStD7L1 (PDB ID: 3NHT). A crystal of CxD7L1 that belonged to I212121 space 220 group and diffracted to 1.97 Å resolution was used to collect a data set ( The CxD7L1 protein fold consists of 17 helical segments stabilized by 5 disulfide bonds linking 225 C18 with C51, C47 with C104, C154 with C186, C167 with C295 and C228 with C242 ( Fig. 5a - further along the ADP molecule, we find that S267 interacts strongly with and fixes the ribose 240 ring of ADP with its hydroxyl group involved in 2 hydrogen bonds with both O2' and O3'. In 241 addition, the ribose oxygen O2' forms a hydrogen bond with a water molecule and ND2 of N265 242 binds to O5' of the sugar. Arginine 271 makes a hydrogen bond to N265 so that it is positioned 243 favorably to engage in electrostatic interaction with the alpha phosphate. Lysine 146 is also in a 244 location that can potentially be involved in electrostatic interaction with the alpha phosphate.
245
Arginine 133 forms 2 salt bridges with the beta phosphate of ADP, with NH1 and NH2 of R133 binding to O1B and O3B of ADP respectively, which may explain the similar binding affinities 247 between ATP and ADP and the lower affinity of AMP, which lacks the beta phosphate. 
255
Hydrogen bonds are colored in yellow.
256
Although the superposition of structures of CxD7L1, AeD7 (PDB:3DZT), and AnStD7L1
257
(PDB:3NHT) showed a similar overall structure (Fig. 6a) , the protein sequences only share 20% 258 amino acid identity and some of the essential residues involved in the lipid and biogenic amine 259 binding are missing in CxD7L1 ( Fig. 1 and Supplementary Fig. S3 ). Moreover, CxD7L1 showed amino acid charges that completely change the nature of the binding pockets (Fig. 6b ). The 265 residues involved in ADP binding were not conserved in other D7 homologs (Fig. 1) .
266
Although most of the residues were present in D7 long proteins from Culex tarsalis 267 ( Supplementary Fig. S3 ) no experimental data is available showing that D7L1 from this 268 mosquito retains the ADP binding capacity. dose-dependent inhibition of platelet aggregation by both CxD7L1 and CxD7L2 (Fig. 7a ).
283
Neither CxD7L1 nor CxD7L2 interfered with platelet aggregation induced by high doses of 284 either collagen (Fig. 7b ) or convulxin (Fig. 7c) , an agonist of the platelet GPVI collagen receptor 285 which induces platelet aggregation independently of secondary mediators. 
294
We also investigated the anti-platelet aggregation activity of CxD7L1 and CxD7L2 using ADP at any dose, confirming that CxD7L2 does not target ADP (Fig. 8a) . 
312
We also used U-46619, the stable analog of TXA2 and widely accepted for platelet aggregation 313 studies 13, 14, 26, 27 . When platelets are activated, TXA2 is synthesized from arachidonic acid 314 released from platelet membrane phospholipids. TXA2 is an unstable compound and cannot be 315 evaluated directly as a platelet aggregation agonist ex vivo. CxD7L2 inhibited U-46619-induced platelet aggregation in a dose-dependent manner. However, platelet shape change requires 317 minimal concentrations of TXA2, and it was not prevented by CxD7L2 (Fig. 8b) . Shape change 318 was only abolished in the presence of 1 µM SQ29,548, a specific antagonist of the TXA2 319 receptor (Fig. 8b) . This result is supported by our biochemical data showing that CxD7L2 binds 320 directly to U-46619 in vitro (Fig. 4h ). However, we do not know whether this binding is retained 321 in vivo.
322
To verify that this protein binds the biological active TXA2 ex vivo, we induced platelet 323 aggregation with its biosynthetic precursor, arachidonic acid, so that TXA2 would be released by 324 platelets. CxD7L2 inhibited platelet aggregation induced by arachidonic acid only at high doses 325 of protein (6 µM, Fig. 8b ), most likely due to the low binding affinity observed for U-46619 and 326 arachidonic acid (Table 1) . To further investigate whether this effect was a result of a direct 327 sequestering of TXA2 by CxD7L2, we pre-incubated platelets with indomethacin, a 328 cyclooxygenase-1 inhibitor, that prevents TXA2 biosynthesis. We observed almost no inhibition 329 of low dose collagen-induced platelet aggregation in the presence of CxD7L2 (Fig. 8b) , 330 indicating that the anti-platelet aggregation activity of CxD7L2 is mediated by TXA2 binding.
331
CxD7L1 inhibits platelet aggregation induced by U-46619 in a dose-dependent manner (Fig. 8b) .
332
CxD7L1 does not bind U-46619 as shown by microcalorimetry ( Supplementary Fig. S2 ), but it 333 tightly binds ADP (Fig. 3b , Table 1 ). Platelet aggregation triggered by U-46619, arachidonic 334 acid, and low doses of collagen is highly dependent on ADP 28 . As a confirmation of this 335 dependence, CxD7L1 inhibits platelet aggregation stimulated by either U-46619 or arachidonic 336 acid as effectively as the antagonist of the TXA2 receptor SQ29,548. CxD7L1 also prevented 337 aggregation initiated by low dose of collagen in indomethacin-treated platelets (Fig. 8b) .
Serotonin acts as a potentiator of platelet agonists such as ADP or collagen. Alone, serotonin can 339 initiate platelet aggregation, but in the absence of a more potent agonist, the platelets eventually 340 disaggregate (Fig. 9a ). CxD7L2 tightly binds serotonin (Fig. 4a) . Therefore, the initiation of 341 aggregation produced by serotonin was completely abolished in the presence of equimolar 342 concentrations of the recombinant protein (Fig. 9a) . However, when a higher dose of serotonin 343 was used (10 μM), CxD7L2 was unable to sequester all the serotonin, resulting in no observed 344 inhibition of platelet aggregation (Fig. 9a) . When serotonin and low doses of collagen were used 345 as aggregation agonists, CxD7L1 partially prevented aggregation, presumably due to its ADP 346 binding, while CxD7L2-serotonin binding resulted in full inhibition of platelet aggregation (Fig.   347 9b). Serotonin also potentiated aggregation initiated by low doses of ADP (Fig. 9c ). When 348 platelets were incubated with CxD7L2, the synergistic effect of serotonin and ADP in platelet 349 aggregation was abolished (Fig. 9c) . CxD7L1, as a potent ADP-binder, completely abrogated 350 platelet aggregation initiated by serotonin and ADP combined. In addition, CxD7L2 partially 351 prevented aggregation initiated by serotonin and epinephrine (Fig. 9d ). 
Discussion
361
An arthropod blood feeding event can be considered as a battle between the need of the 362 arthropod to acquire blood and the vertebrate host response to prevent blood loss. The outcome of this battle determines whether the arthropod can complete its life cycle, making a successful 364 blood feeding event a crucial process for the fate of the invertebrate. During a bite, arthropod 365 salivary proteins are injected into the host skin to counteract host hemostatic mediators. In this 366 work, we characterized the structure and function of the salivary D7 long proteins from C. 367 quinquefasciatus mosquitoes and described a novel mechanism of platelet aggregation inhibition 368 for a D7 salivary protein.
369
CxD7L1 and CxD7L2 were found to be expressed in the distal-lateral and medial lobes of C. 
